EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study

Joost Boeckmans, Linnea Widman, Ying Shang, Rickard Strandberg, Axel Wester, Jörn M Schattenberg, Hannes Hagström

European Journal of Internal Medicine · 2025-04 · 134 · 104-113

DOI: 10.1016/j.ejim.2025.02.014 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Journal of Internal Medicine, 2025-04. Verfasst von Joost Boeckmans und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; In Vitro Liver Disease Modelling team - Department of In Vitro Toxicology…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Liver Diseases, Alcoholic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mag-TarmFonden, Swedish Gastroenterology Society, Åke Wiberg Stiftelse, Bengt Ihres Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: It is unclear if the risk of hepatic decompensation or hepatocellular carcinoma (HCC) differs between patients with compensated alcohol-related liver disease (ALD)- and metabolic dysfunction-associated steatotic liver disease (MASLD)-cirrhosis. We investigated the risk to develop hepatic decompensation or HCC based on ALD or MASLD as the underlying etiology of cirrhosis. METHODS: All patients with a new diagnosis in hospital-based outpatient care of ALD- or MASLD-cirrhosis in Sweden between 2002 and 2020 were identified using national registers. Hepatic decompensation was analyzed as a composite outcome with HCC. Cox regression was employed to compare rates of hepatic decompensation or HCC, and subsequent death. RESULTS: 1660 patients with ALD-cirrhosis and 943 patients with MASLD-cirrhosis were identified. The median ages were 64 years (IQR 57-70) and 69 years (IQR 62-75) in patients with ALD- and MASLD-cirrhosis, respectively. Patients with ALD-cirrhosis consisted of 69.4 % males, compared to 47.6 % males in the MASLD-cirrhosis group. 581 (35 %) patients with ALD-cirrhosis and 284 (30 %) patients with MASLD-cirrhosis developed hepatic decompensation or HCC (median follow-up time: 25 months), resulting in an adjusted hazard ratio of 1.12 (ALD- vs. MASLD-cirrhosis, 95 %-confidence interval=0.88-1.41). The adjusted risk of mortality afterwards was lower in patients with ALD-cirrhosis compared to patients with MASLD-cirrhosis (adjusted hazard ratio 0.62, 95 %-confidence interval=0.39-0.97). CONCLUSIONS: The risk of hepatic decompensation or HCC is comparable in patients with ALD- and MASLD-cirrhosis, but the risk of mortality after a decompensation event or HCC tends to be higher in patients with MASLD-cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisLiver Diseases, AlcoholicHumansMaleFemaleMiddle AgedAgedSwedenRisk FactorsProportional Hazards ModelsRegistriesCohort Studies

Stichwörter der Autor:innen

Alcohol-related liver diseaseCirrhosisEpidemiologyEtiologyMetabolic dysfunction-associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; In Vitro Liver Disease Modelling team - Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Univ…
  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Electronic address: linnea.widman@ki.se.
  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Electronic address: ying.shang@ki.se.
  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Electronic address: rickard.strandberg@ki.se.
  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Electronic address: axel.wester@ki.se.
  • Department of Medicine II, University Medical Center Homburg, Homburg and Saarland University, Saarbrücken, Germany. Electronic address: joern.schattenberg@uks.eu.

Förderung

  • Mag-TarmFonden, Swedish Gastroenterology Society
  • Åke Wiberg Stiftelse
  • Bengt Ihres Foundation
  • Stockholms Läns Landsting
  • Cancerfonden
  • Swedish Research Council

Zitieren

APA

Boeckmans, J., Widman, L., Shang, Y., Strandberg, R., Wester, A., Schattenberg, J. M., & Hagström, H. (2025). Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study. European Journal of Internal Medicine, 134, 104-113. https://doi.org/10.1016/j.ejim.2025.02.014

Vancouver

Boeckmans J, Widman L, Shang Y, Strandberg R, Wester A, Schattenberg JM, et al. Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study. European Journal of Internal Medicine. 2025;134:104-113. doi:10.1016/j.ejim.2025.02.014

BibTeX
@article{Boeckmans2025,
  author = {Boeckmans, Joost and Widman, Linnea and Shang, Ying and Strandberg, Rickard and Wester, Axel and Schattenberg, Jörn M and Hagström, Hannes},
  title = {Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study},
  journal = {European Journal of Internal Medicine},
  year = {2025},
  volume = {134},
  pages = {104--113},
  doi = {10.1016/j.ejim.2025.02.014}
}
Kostenlos starten →